银屑病患者接受生物制剂治疗的真菌感染风险:单中心回顾性队列研究
该单中心回顾性队列研究纳入592例接受生物制剂治疗的银屑病患者,评估真菌感染的发生率及风险。生物制剂类型(P = .004)、开始生物制剂治疗时年龄(OR 1.04;95% CI 1.02-1.06)和糖尿病(OR 2.40;95% CI 1.20-4.79)为真菌感染风险因素。
要点
- 592例接受生物制剂的银屑病患者中12.3%发生真菌感染。
- IL-17抑制剂比其他生物制剂更常关联真菌感染,尤其念珠菌病。
- 开始治疗时年龄和糖尿病是独立风险因素。
核心结论
- 接受IL-17抑制剂治疗的银屑病患者比其他生物制剂更易发生真菌感染,尤其是念珠菌病。
- 开始生物制剂治疗时年龄和糖尿病发病也是真菌感染的独立风险因素。
研究设计与样本
- 单中心回顾性队列研究,纳入592例接受生物制剂治疗的银屑病病例。
主要发现
- 真菌感染发生更频繁地与IL-17抑制剂使用相关,而非其他生物制剂。
- 真菌感染风险因素包括生物制剂类型(P = .004)、开始生物制剂治疗时年龄(OR 1.04;95% CI 1.02-1.06)和糖尿病(OR 2.40;95% CI 1.20-4.79)。
临床怎么用
- 对银屑病患者使用IL-17抑制剂时,应警惕真菌感染风险,尤其念珠菌病。
- 开始生物制剂治疗时年龄较大或合并糖尿病的患者,需加强真菌感染监测。
局限性
- 本回顾性研究未纳入未接受生物制剂治疗的患者。
- 许多病例中使用的生物制剂类型发生了改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of fungal infection in patients with psoriasis receiving biologics is not fully understood in clinical practice. OBJECTIVE: To assess the incidence and the risk of fungal infection onset in patients with psoriasis receiving biologics. METHODS: A retrospective cohort study of 592 psoriasis cases treated with biologics at a single center. RESULTS: Seventy-three (12.3%) of the 592 cases involved a fungal infection. Fungal infection occurrence was more frequently associated with the use of interleukin (IL) 17 inhibitors than of other biologics. The risk factors of fungal infection were the type of biologic agent (P = .004), age at the start of biologic therapy (odds ratio, 1.04; 95% CI, 1.02-1.06), and diabetes mellitus (odds ratio, 2.40; 95% CI, 1.20-4.79). LIMITATIONS: The present, retrospective study did not include patients who did not receive biologic therapy. Moreover, the type of biologic agent used was changed in many cases. CONCLUSIONS: Patients with psoriasis treated with IL-17 inhibitors were more likely to cause fungal infections, especially candidiasis, than other biologics. Moreover, the age at the start of biologic therapy and diabetes mellitus onset were also independent risk factors of fungal infection.
引用
- Minami Y, Hiruma J, Harada K, et al. Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study. J Am Acad Dermatol. 2024. PMID: 39357650. doi:10.1016/j.jaad.2024.09.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。